1. Home
  2. PRAX

PRAX

Praxis Precision Medicines Inc.

Logo Praxis Precision Medicines Inc.

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

as 04-12-2024 3:51pm EST

$
-
-
.
-
-
+$
-
.
-
-
+
-
.
-
-
%

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.

Founded: N/A Country:
United States
United States
Employees: N/A City: BOSTON
Market Cap: 858.8M IPO Year: 2020
Target Price: $103.00 AVG Volume (30 days): 193.0K
Analyst Decision: Strong Buy Number of Analysts: 4
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -18.69 EPS Growth: N/A
52 Week Low/High: $12.45 - $67.21 Next Earning Date: 05-09-2024
Revenue: $2,447,000 Revenue Growth: N/A
Revenue Growth (this year): -4.13% Revenue Growth (next year): -35.98%

Share on Social Networks: